ATE361318T1 - Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen - Google Patents

Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen

Info

Publication number
ATE361318T1
ATE361318T1 AT01935466T AT01935466T ATE361318T1 AT E361318 T1 ATE361318 T1 AT E361318T1 AT 01935466 T AT01935466 T AT 01935466T AT 01935466 T AT01935466 T AT 01935466T AT E361318 T1 ATE361318 T1 AT E361318T1
Authority
AT
Austria
Prior art keywords
april
taci
bcma
cell
agp
Prior art date
Application number
AT01935466T
Other languages
English (en)
Inventor
Lars Eyde Theill
Gang Yu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE361318T1 publication Critical patent/ATE361318T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01935466T 2000-05-12 2001-05-14 Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen ATE361318T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20403900P 2000-05-12 2000-05-12
US21459100P 2000-06-27 2000-06-27

Publications (1)

Publication Number Publication Date
ATE361318T1 true ATE361318T1 (de) 2007-05-15

Family

ID=26899121

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01935466T ATE361318T1 (de) 2000-05-12 2001-05-14 Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen

Country Status (10)

Country Link
US (2) US6774106B2 (de)
EP (1) EP1280826B1 (de)
JP (1) JP2003533218A (de)
AT (1) ATE361318T1 (de)
AU (3) AU2001263114A1 (de)
CA (1) CA2408617A1 (de)
DE (1) DE60128216T2 (de)
ES (1) ES2287130T3 (de)
MX (1) MXPA02011130A (de)
WO (2) WO2001087979A2 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
EP1210425B2 (de) * 1999-08-17 2015-06-17 Biogen MA Inc. Baff rezeptor (bcma), ein immunoregulatorisches mittel
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
ATE329610T1 (de) * 2000-02-16 2006-07-15 Genentech Inc Anti-april antikörper und hybridomazellen
US20040013674A1 (en) * 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
US7371388B1 (en) 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
PT2281843T (pt) * 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
EP2267018A3 (de) * 2000-08-18 2011-04-20 Human Genome Sciences, Inc. Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
US20030091565A1 (en) * 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
WO2002046231A2 (en) * 2000-12-07 2002-06-13 The University Of British Columbia Caml-binding peptides
EP2301971A1 (de) * 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antikörper, die sowohl BCMA als auch TACI binden
DK1436003T3 (da) * 2001-05-24 2010-03-15 Zymogenetics Inc TACI-immunoglobulin-fusionsproteiner
EP1401870A4 (de) 2001-05-24 2006-04-19 Human Genome Sciences Antikörper gegen tumor necrosis factor delta (april)
HUP0500992A3 (en) * 2001-08-03 2007-11-28 Genentech Inc Tacis and br3 polypeptides and uses thereof
AU2002364954A1 (en) * 2001-11-16 2003-07-15 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
JP2005533863A (ja) * 2002-07-25 2005-11-10 ジェネンテック・インコーポレーテッド Ｔａｃｉ抗体とその用途
AU2003284260B2 (en) * 2002-10-11 2010-06-03 Zymogenetics, Inc. Production of homotrimeric fusion proteins
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
PT2272868E (pt) 2003-06-05 2015-07-07 Genentech Inc Terapêutica de combinação para distúrbios de células b
US20050118728A1 (en) * 2003-07-02 2005-06-02 Caldwell Kevin K. Two-layer antibody capture system
JP2008505607A (ja) * 2004-01-29 2008-02-28 ジェネンテック・インコーポレーテッド Ｂｃｍａの細胞外ドメインの変異体とその使用法
EP1812472A1 (de) * 2004-11-04 2007-08-01 Genentech, Inc. An baff und/oder april bindende polypeptide
US7947805B2 (en) 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
AR059945A1 (es) * 2005-08-09 2008-05-14 Zymogenetics Inc Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion taci-ig
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
AU2006344395B2 (en) * 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2629306A1 (en) * 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
NZ572373A (en) 2006-05-15 2012-02-24 Ares Trading Sa Methods for treating rheumatoid arthritis using a taci-ig fusion molecule
EA017733B1 (ru) * 2006-08-28 2013-02-28 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
LT2061803T (lt) * 2006-08-28 2019-11-25 Ares Trading Sa Fc turinčių baltymų gryninimo būdas
WO2008088422A2 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
PL2219675T3 (pl) * 2007-11-12 2014-04-30 Ares Trading Sa Formulacja dla białek fuzyjnych TACI-immunoglobulina
JP5739326B2 (ja) 2008-04-25 2015-06-24 ザイモジェネティクス， インコーポレイテッド Ｂ細胞上でのｂｃｍａタンパク発現レベル及び診断法における使用
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20110014190A1 (en) * 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
SI2403528T1 (sl) * 2009-03-02 2016-07-29 Aduro Biotech Holdings, Europe B.V. Protitelesa proti proliferacijo inducirajočemu ligandu (april)
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
ES2712102T3 (es) * 2010-09-10 2019-05-09 Tigenix S A U Medios y métodos de cultivo de células madre
MX353143B (es) 2011-02-28 2017-12-20 Genentech Inc Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
NL2011406C2 (en) * 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
US10435453B2 (en) 2014-02-07 2019-10-08 Mcmaster University Trifunctional T cell-antigen coupler and methods and uses thereof
WO2016003876A1 (en) 2014-07-03 2016-01-07 Oklahoma Medical Research Foundation Treatment of multiple sclerosis and neuromyelitis optica
SI3380522T1 (sl) 2015-11-25 2024-02-29 Visterra, Inc. Molekule protitelesa proti APRIL in uporabe le-teh
JP7432363B2 (ja) 2016-06-21 2024-02-16 テネオバイオ， インコーポレイテッド Ｃｄ３結合抗体
FI4050034T3 (fi) 2016-09-14 2024-06-10 Teneoone Inc Cd3:een sitoutuvia vasta-aineita
EP4215548A1 (de) 2016-12-21 2023-07-26 Teneobio, Inc. Nur schwerkettige anti-bcma-antikörper
AU2018289493A1 (en) * 2017-06-20 2019-12-12 Dana-Farber Cancer Institute, Inc. Methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction
EP3642237A2 (de) 2017-06-20 2020-04-29 Teneobio, Inc. Nur schwerketten-anti-bcma-antikörper
US11517591B2 (en) * 2017-09-01 2022-12-06 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens
EP3694997A4 (de) 2017-10-12 2021-06-30 Mcmaster University T-zellen-antigen-koppler mit y182t-mutation und verfahren und verwendungen davon
EP3694871A4 (de) 2017-10-13 2021-11-10 Harpoon Therapeutics, Inc. B-zellreifungs-antigenbindende proteine
CU20200089A7 (es) 2018-06-01 2021-07-02 Novartis Ag Moléculas de unión contra bcma
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
AU2019346466A1 (en) 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CA3140816A1 (en) 2019-06-14 2020-12-17 Nathan Trinklein Multispecific heavy chain antibodies binding to cd22 and cd3
WO2021121250A1 (zh) * 2019-12-17 2021-06-24 深圳市菲鹏生物治疗股份有限公司 Bcma结合抗体及其用途
CA3176792C (en) 2020-04-29 2024-06-18 Katherine HARRIS Anti-cd3 and anti-bcma bispecific antibodies wth modified heavy chain constant regions
KR20230029622A (ko) 2020-05-08 2023-03-03 알파인 이뮨 사이언시즈, 인코포레이티드 April 및 baff 억제 면역조절 단백질 및 사용 방법
WO2022256449A1 (en) 2021-06-01 2022-12-08 Triumvira Immunologics Usa, Inc. Claudin 18.2 t cell-antigen couplers and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
CA2118130A1 (en) 1992-04-14 1993-10-28 Jean M. J. Frechet Dendritic based macromolecules and method of production
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
CA2665133A1 (en) 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine .alpha.
WO1998027114A2 (en) 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
CA2292899A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
IL133315A0 (en) 1997-06-06 2001-04-30 Regeneron Pharma Ntn-2 member of tnf ligand family
US6171787B1 (en) 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
CA2303424A1 (en) 1997-09-12 1999-03-18 Jurg Tschopp Kay - a novel immune system protein
HUP0004611A3 (en) * 1997-09-12 2002-04-29 Apotech R & D Sa April- a novel protein with growth effects
US6297022B1 (en) 1997-10-08 2001-10-02 Smithkline Beecham Corporation Method of identifying agonists and antagonists for tumor necrosis related receptor TR1
AU1700999A (en) 1997-11-26 1999-06-15 Eli Lilly And Company Tnf ligand family gene
NZ504548A (en) 1997-12-03 2003-06-30 Genentech Inc Polypeptides and nucleic acids encoding human chordin
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
AU2212299A (en) 1998-01-05 1999-07-26 Genentech Inc. Compositions and methods for the treatment of tumor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1141274B2 (de) * 1999-01-07 2014-11-12 ZymoGenetics, Inc. Lösliche rezeptoren br43x2 und verfahren zu deren therapeutischen verwendung
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
EP1210425B2 (de) * 1999-08-17 2015-06-17 Biogen MA Inc. Baff rezeptor (bcma), ein immunoregulatorisches mittel
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
ATE329610T1 (de) * 2000-02-16 2006-07-15 Genentech Inc Anti-april antikörper und hybridomazellen

Also Published As

Publication number Publication date
CA2408617A1 (en) 2001-11-22
US20020081296A1 (en) 2002-06-27
US6774106B2 (en) 2004-08-10
DE60128216D1 (de) 2007-06-14
DE60128216T2 (de) 2008-01-10
WO2001087977A2 (en) 2001-11-22
MXPA02011130A (es) 2003-03-10
ES2287130T3 (es) 2007-12-16
AU2001263114A1 (en) 2001-11-26
US20020086018A1 (en) 2002-07-04
WO2001087979A3 (en) 2002-05-30
WO2001087979A2 (en) 2001-11-22
AU2001261557B2 (en) 2005-06-30
AU6155701A (en) 2001-11-26
JP2003533218A (ja) 2003-11-11
EP1280826A2 (de) 2003-02-05
WO2001087977A3 (en) 2002-06-20
EP1280826B1 (de) 2007-05-02

Similar Documents

Publication Publication Date Title
ATE361318T1 (de) Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen
HUS1700012I1 (hu) Bruton-tirozinkináz inhibitorok
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
ATE442850T1 (de) Kappa-opioid-rezeptor-liganden
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
GB2431346C (en) A combination composition comprising paracetamol and ibuprofen
SG149872A1 (en) Antagonists of the bradykinin b1 receptor
RS89104A (en) Novel antagonists of mcp proteins
TNSN05315A1 (en) Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
ATE286074T1 (de) Gegen ccr5 gerichtete antikörperkonstrukte und ihre verwendung in der behandlung von autoimmunkrankheiten
EP1611151A4 (de) Stq-peptide
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
ATE414776T1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties